Active Ingredient(s): Imipenem + Cilastatin +Relebactam
FDA Approved: * July 16, 2019
Pharm Company: * MERCK SHARP DOHME
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Recarbrio Overview

Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio,[1] is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections.[2][3][4][5] It is administered via intravenous injection.[6][1] The most common adverse reactions include...

Read more Recarbrio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Recarbrio Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Imipenem + Cilastatin +Relebactam
  • Injection: 500mg + 500mg + 250mg
  • Powder: 500mg/vial + 500mg/vial + 250mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Recarbrio: (1 result)

Sorted by National Drug Code
  • 0006-3856 Recarbrio Intravenous Injection, Powder, for Solution by Merck Sharp & Dohme Corp.

Drugs with one or more similar ingredients: (3 results)